Schizophrenia is frequently a chronic and disabling disorder, characterized by
heterogeneous positive and negative symptom constellations. The objective of this review …

Negative and cognitive deficit symptoms in schizophrenia remain an unmet clinical need.
Improved understanding of the neuro-and psychopathology of cognitive dysfunction in the …

Background Although predominant negative symptoms of schizophrenia can be severe
enough to cause persistent impairment, effective treatment options are lacking. We aimed to …

Major depression is a debilitating and recurrent disorder with a substantial lifetime risk and a
high social cost. Depressed patients generally display co-morbid symptoms, and depression …

Schizophrenia is characterized by positive, negative, cognitive, and affective symptoms.
Antipsychotic medications, which work by blocking the dopamine D 2 receptor, are the …

Dopamine (DA) is a critical neurotransmitter in the mammalian central nervous system
(CNS). The cerebral dopaminergic system is implicated in the pathophysiology of several …

Asenapine is a novel psychopharmacologic agent under development for the treatment of
schizophrenia and bipolar disorder. We determined and compared the human receptor …

Introduction Cariprazine is an orally active and potent D 3 and D 2 partial agonist with
preferential binding to D 3 receptors in development for the treatment of schizophrenia and …

After a 12-year search for the antipsychotic receptor, the binding site was discovered and
labelled by [3H] haloperidol in 1975. Of the various neurotransmitters, dopamine was the …

Repeated exposure to drugs of abuse produces long‐term molecular and neurochemical
changes that may explain the core features of addiction, such as the compulsive seeking …